Singapore, Aug. 12 -- Innovent Biologics, Inc. and Daiichi Sankyo have entered into an exclusive agreement for the commercialisation of Vanflyta(R) (quizartinib) in China.

Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta(R) while Innovent Biologics holds sole commercialisation rights for Vanflyta(R) in China, leading market promotion.

VANFLYTA was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive ...